Direct Access Microbial Dark Matter for AI-Driven Polypharmacology Drug Discovery

Summary – The pharmaceutical industry is currently trapped by two opposing forces—the saturation of common natural scaffolds and the infinite dilution of synthetic libraries—which collectively drive Eroom’s Law and push the cost of discovery to unsustainable levels. Our strategy reverses this trend by deploying a hybrid model that mines the “dark matter of biology"—the vast, unexplored chemical grammars hidden in rare biomes—to serve as the structural priors for AI-driven design. By decoding these evolutionary rules first, we effectively bypass the high failure rates of random synthetic screening, ensuring that our earliest preclinical candidates already possess the “bilingual" capacity to satisfy both therapeutic targets and biological safety constraints. This approach front loads value creation, shifting the investment opportunity to the earliest preclinical stage where the de risking occurs, thereby securing the highest possible ROI as envisioned by our Proof of Concept WL-Portfolio asset.